Travere Therapeutics (NASDAQ:TVTX) Insider William Rote Sells 12,446 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider William Rote sold 12,446 shares of Travere Therapeutics stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $32.87, for a total transaction of $409,100.02. Following the completion of the sale, the insider directly owned 109,087 shares of the company’s stock, valued at approximately $3,585,689.69. The trade was a 10.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Travere Therapeutics Price Performance

TVTX stock opened at $32.84 on Wednesday. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. The business has a 50-day simple moving average of $34.11 and a two-hundred day simple moving average of $27.76. The company has a market capitalization of $2.94 billion, a P/E ratio of -30.98, a price-to-earnings-growth ratio of 1.01 and a beta of 0.83. Travere Therapeutics, Inc. has a 52-week low of $12.91 and a 52-week high of $42.13.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Negative Sentiment: Multiple senior insiders sold large blocks of shares on Feb 3, including CEO Eric M. Dube (100,087 shares, ~18.8% reduction in his position) and several executives (CFO, CAO and other officers) reducing holdings by ~5–10% each — a broad, same-day executive sell-off that can signal rotation or prompt investor concern about near-term insider confidence. CEO Form 4
• Negative Sentiment: A recent article questions Travere’s disclosure and risk narrative, flagging potential credibility concerns that could amplify selling or increase short-term volatility if investors seek more clarity from management. Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative?

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in Travere Therapeutics during the second quarter valued at approximately $33,000. First Horizon Corp bought a new stake in shares of Travere Therapeutics during the 3rd quarter worth $36,000. Torren Management LLC purchased a new position in Travere Therapeutics in the fourth quarter worth $38,000. Comerica Bank increased its stake in Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after acquiring an additional 492 shares during the last quarter. Finally, Garner Asset Management Corp purchased a new stake in Travere Therapeutics during the fourth quarter valued at about $69,000.

Analyst Ratings Changes

A number of brokerages recently weighed in on TVTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $47.00 target price on shares of Travere Therapeutics in a research note on Friday, November 28th. Wall Street Zen raised shares of Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Piper Sandler upped their price objective on Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Finally, Guggenheim reissued a “buy” rating and issued a $49.00 target price on shares of Travere Therapeutics in a research report on Wednesday, January 14th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.86.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.